Document Type
Patent
Patent Number
US 9221877B2
Abstract
Conjugating LHRH to curcumin (LHRH-Curcumin) substantially enhances the bioavailability of curcumin, targets it to cells expressing LHRH receptors, facilitates intravenous administration, and increases the anti-cancer efficacy of curcumin. The conjugate may be used against cancer cells that express the LHRH receptor: pancreas, prostate, breast, testicular, uterine, ovarian, melanoma. LH-Curcumin conjugates may be used against cancer cells that express the LH receptor: prostate, breast, ovary, testis, uterus, pancreas, and melanoma.
Application Number
US13/119,549
Assignees
Louisiana State University
Publication Date
10-29-2015
Recommended Citation
Hansel, W., Aggarwal, S., & Hammer, R. (2015). Curcumin Conjugates for Treating and Preventing Cancers. Retrieved from https://repository.lsu.edu/pbrc_patents/5